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Abstract
· AIM: To compare therapeutic effects of intravitreal
triamcinolone acetonide (IVTA) versus intravitreal
bevacizumab (IVB) injections for bilateral diffuse diabetic
macular edema (DDME).
·METHODS: Forty eyes of 20 patients with bilateral
DDME participated in this study. For each patient, 4 mg/
0.1 mL IVTA was injected to one eye and 2.5 mg/0.1 mL
IVB was injected to the other eye. The effects of injection
for diabetic macular edema (DME) were evaluated using
best -corrected visual acuity (BCVA), central macular
thickness (CMT) by optical coherence tomography (OCT)
and intraocular pressure (IOP) by applanation tonometer.
Patients underwent eye examinations, including BCVA,
CMT, and IOP at pre-injection, 1, 4, 8, 12 and 24wk after
injection. During the follow -up, second injections were
performed to eyes which have CMT greater than 400 滋m
at 12wk for salvage therapy.
·RESULTS: BCVA (logarithm of the minimum angle of
resolution) at pre -injection, 1, 4, 8, 12 and 24wk after
injection was 0.71依0.19, 0.62依0.23, 0.63依0.12, 0.63依0.13,
0.63依0.14 and 0.61依0.24 in the IVTA group and 0.68依0.25,
0.61依0.22, 0.60依0.24, 0.62依0.25, 0.65依0.26 and 0.59依0.25
in the IVB group, respectively. CMT (滋m) at pre-injection,
1, 4, 8, 12 and 24wk after injection was 544依125, 383依96,
335依87, 323依87, 333依92, 335依61 in the IVTA group and
514依100, 431依86, 428依107, 442依106, 478依112, 430依88 in
the IVB group respectively. Reduction ratios of mean
CMT were 29% at 1wk, 38% at 4wk, 40% at 8wk, 38% at
12wk, and 38% at 24wk in the IVTA group. Second IVTA
injections were performed to the 6 eyes (30%) at 12wk.
Reduction ratios of mean CMT were 16% at 1wk, 17% at
4wk, 14% at 8wk, 7% at 12wk, and 16% at 24wk in the
IVB group. Second IVB injections were performed to the
15 eyes (75%) at 12wk.
·CONCLUSION: This study showed earlier and more
frequent macular edema recurrences in the eyes treated
with bevacizumab compared with the ones treated with
triamcinolone acetonide. Triamcinolone acetonide was
found to provide more efficient and long-standing effect
in terms of reducing CMT compared with the
bevacizumab.
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INTRODUCTION
M acular edema is the main cause of visual loss inpatients with diabetic retinopathy, which may occur at
any stage of diabetic retinopathy and often bilaterally [1]. The
Early Treatment of Diabetic Retinopathy Study (ETDRS)
indicates that focal/grid laser photocoagulation for clinically
significant macular edema effectively reduces the risk of
moderate vision loss [2]. Later studies showed that grid laser
photocoagulation has limited efficacy, and may cause
decreased vision because of progressive macular scar and
subretinal fibrosis [3-5]. At present, there have been several
therapies for the treatment of diabetic macular edema
(DME) such as intravitreal steroids and anti-vascular
endothelial growth factor (VEGF) injections. Ranibizumab
and bevacizumab are two main anti-VEGF agents for DME.
Although ranibizumab has been approved by the United
States Food and Drug Administration for the treatment of
DME, bevacizumab, which costs much less than
ranibizumab, is commonly used as an off-label therapeutic
option in treating DME. Many studies have indicated
intravitreal bevacizumab (IVB) was effective for reducing
DME[6-8]. Triamcinolone acetonide (TA), one of corticosteroids,
has the effect of anti-inflammatory and anti-angiogenic.
Many reports have demonstrated the usefulness of intravitreal
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TA (IVTA) in patients with DME[9,10]. With the increasing use
of IVB and IVTA, it is of interest to confirm which agent is
more effective and safe. In the literature apart from one
study, efficacy of IVTA and IVB therapies have been
compared by applying them on only one eye of different
patients. The purpose of this prospective, clinical controlled
study to compare the efficacy of IVTA versus IVB for
bilateral diffuse DME (DDME), and also their possible side
effects in both eyes of the same patient.
SUBJECTS AND METHODS
Subjects Forty eyes of 20 patients with bilateral DDME
were included in this study. The study was approved by the
local ethic committee of Baskent University and written
inform concent was taken from all patients according to the
Declaration of Helsinki. Ophthalmological examination
findings were included; best-corrected visual acuity (BCVA)
which was measured with the Snellen chart and then
converted to logMAR, intraocular pressure (IOP) by
Goldmann applanation tonometry and biomicroscopic
anterior-posterior segment findings. The diagnosis of diabetic
retinopathy and macular edema was made with slit-lamp
fundus examination and also by fundus fluorescein
angiography (FFA). Retinal thickness was measured by
CirrusTM HD-OCT (Carl Zeiss Inc. MEDITEC., Dublin, CA,
USA), 512伊128 cube map using the macular scan pattern.
Patients were included if they had: 1) retinal thickening of
two or more disk areas involving some portion of the foveal
avascular zone and diffuse fluorescein leakage involving the
fovea and most of the macular area on fluorescein
angiography; 2) logMAR BCVA of 0.5 or worse; and 3)
central macular thickness (CMT) greater than 300 滋m on
OCT. Exclusion criterias were: 1) previous therapies for
macular edema, including grid-laser treatment, intravitreal
injection of any drugs, and/or vitreous surgery; 2) macular
ischemia on fluorescein angiography; 3) aphakic or 1 eye
phakic and other eye pseudophakic patients; 4) glycosylated
haemoglobin (HbA1c) level above 10% ; 5) history of
glaucoma or ocular hypertension; 6) panretinal
photocoagulation history shorter than 3mo; 7) an ocular
condition other than diabetes mellitus (DM) that, the
investigator thinks that might affect macular edema or alter
visual acuity during the course of the study such as retinal
vein occlusion, uveitis or other ocular inflammatory disease,
epiretinal membrane, macular degeneration, vitreomacular
traction; 8) systemic corticosteroid therapy; 9) history of
thromboembolic event or current use of anticoagulative
medication other than acetylsalicylic acid; 10) uncontrolled
hypertension.
Intravitreal injections were performed in the outpatient clinic,
under sterile conditions. The 2.5 mg/0.1 mL of bevacizumab
was injected to one eye (Avastin, Genentech, Inc., San
Francisco, California, USA), and 4 mg/0.1 mL of TA
(Kenacort-A, 40 mg/mL, Bristol-Myers Squibb, New Jersey,
USA) was injected to the other eye for every patient with 1d
interval. All patients were examined for control 1d after each
injection. After the injection 0.3% ofloxacin drops were
prescribed four times per day for a week.
According to the CMT values determined by OCT, TA was
injected to the eye with thicker CMT and bevacizumab was
injected to the other eye in first patient and subsequently in
the next patient bevacizumab was injected into the eye with
thicker CMT and TA was injected to the other eye. TA and
bevacizumab were injected into the eye with thicker CMT of
consecutive patients by turn to make possible equal
conditions of macular edema between groups. Reduction
ratios for CMT values were calculated by the formula; final
CMT-initial CMT/initial CMT at 1, 4, 8, 12 and 24wk.
Patients' visual acuity, CMT, IOP data were evaluated at 1, 4,
8, 12 and 24wk. During the follow-up, same injections were
repeated to patients who have CMT greater than 400 滋m at
12wk for the salvage therapy.
Statistical Analysis Statistical analysis of continuous
variables with normal distribution was checked for
compliance Shapiro-Wilk test. Variances were analyzed with
the homogeneity of the Levene test. Parametric tests on
pre-conditions are not fulfilled; in order to compare the two
drug groups Mann-Whitney test was used. Friedman test
and then with the period between six different multiple
comparison methods were compared with Bonferroni-Dunn
test. Results were expressed as mean 依standard deviation.
Data set SPSS program (SPSS version 15.0, SPSS Inc.,
Chicago, IL, USA) were analyzed using.
RESULTS
Forty eyes of 20 patients were included in this study. There
were 10 (50%) female and 10 (50%) male patients, with
mean age of 62 (range 53-74)y. All patients had type 2 DM,
and the duration of DM from 10 to 20y. Ten (50%) patients
had comorbide hypertension and were taking oral
antihypertensive drugs. Thirteen (65% ) patients had pan-
retinal photocoagulation in both eyes. Patients had no ocular
disease except refractive errors or cataract. There wasn't
concurrent retinal or optic nerve disorder other than diabetic
retinopathy. Four (20%) patients had bilateral pseudophakic,
the remaining 16 (80%) patients had phakic.
BCVA was 0.71 依0.19 logMAR in the IVTA group and
0.68依0.25 logMAR in the IVB group at baseline and there
were not significant differences between these groups
( =0.237). BCVA improved at one week after the injection
(0.62 依0.23 logMAR, <0.001) in the IVTA injected eyes
and remained at the same level up to 24wk (0.61依0.24 logMAR,
<0.001). Visual acuity in the bevacizumab injected eyes
statistically significant improved at 1, 4, and 24wk (0.61依0.22,
0.60依0.24, 0.59依0.25 =0.001). However, at 12wk, visual
acuity returned to the initial level (0.65依0.26). Between these
551
two groups, visual acuity improvement was clinically
significant in favor of triamcinolone acetonide only at first
week ( =0.055). Other time points of 4, 8, 12 and 24wk
there were not statistically significant differences ( =0.247,
=0.142, =0.294, =0.206; Table 1).
Before the administration of the drugs baseline average CMT
value was found 544依125 滋m in the IVTA group, 514依100 滋m
in the IVB group, and there was no statistically significant
difference between the two groups ( =0.715). One week
after IVTA injection, CMT values were significantly
decreased (383 依96 滋m, =0.001) and these decrease
continued up to 24wk. Although, triamcinolone acetonide
injection was administered at 12wk second time to 6 (30%)
eyes in which CMT values greater than 400 滋m. Average
CMT value was 335 依61 滋m at 24wk and decrease was
statistically significant compared with baseline and 12wk
values ( =0.001). After intravitreal injection of bevacizumab
CMT values statistically significant decreased (431依86 滋m,
=0.001) at 1wk and decrease continued until to 8wk.
Average CMT value increased to 442依112 滋m at 12wk and
this change statistically insignificant compared with basale
CMT. Second injection was administered at 12wk to 15
(75%) eyes in which CMT greater than 400 滋m. At 24wk,
the decrease of the CMT values were statistically significant
compared with the baseline and 12wk values (430依88 滋m,
=0.001). Between these two groups, there was a statistically
significant difference of CMT in favor for IVTA at all time
points ( =0.045, =0.007, =0.001, =0.001, =0.001;
Table 2, Figure 1).
Reduction ratios of mean CMT were 29% at 1wk, 38% at
4wk, 40% at 8wk, 38% at 12wk, and 38% at 24wk in the
IVTA group. And the reduction ratios of mean CMT were
16% at 1wk, 17% at 4wk, 14% at 8wk, 7% at 12wk, and 16%
at 24wk in the IVB group.
Average IOP values at baseline 14.6 mm Hg in the IVTA
group, and 14.8 mm Hg in the IVB group and difference
were not significant between the groups ( =0.862). One
month after the injection, IOP in the IVTA group showed a
statistically significant increase and then gradually increased
with time ( =0.001). Four (20%) patients whose IOP values
were higher than 21 mm Hg, treated with topical
antiglaucomatous theraphy. In contrast, IOP in the
bevacizumab-treated eyes did not show a statistically
significant change during the clinical course. At 8, 12 and
24wk IOP in the IVTA group was significantly higher than
the IVB group ( =0.002, =0.002, =0.007; Table 3).
None of the patients who received IVB or IVTA, displayed a
systemic side effect or an ocular complication associated with
the applied invasive procedure. The development or
progression of lens opacities was occurred in 4 (25%) eyes in
the IVTA group. Two of four (50%) eyes that had second
Table 1 Alteration of logMAR visual acuity after each treatment in patients with bilateral DDME 
Treatment group Basale 1wk 4wk 8wk 12wk 24wk 
Triamcinolone 0.71±0.19 0.62±0.23 0.63±0.12 0.63±0.13 0.63±0.14 0.61±0.24 
Bevacizumab 0.68±0.25 0.61±0.22 0.60±0.24 0.62±0.25 0.65±0.26 0.59±0.25 
P  0.237 0.055 0.247 0.142 0.294 0.206 
 
Table 2 Alteration of central macular thickness after each treatment in patients with bilateral DDME 
Treatment group Basale 1wk 4wk 8wk 12wk 24wk 
Triamcinolone 544±125 383±96 335±87 323±87 333±92 335±61 
Bevacizumab 514±100 431±86 428±107 442±106 478±112 430±88 
P 0.715 0.045 0.007 0.001 0.001 0.001 
 
Table 3 Alteration of intraocular pressure after each treatment in patients with bilateral DDME 
Treatment group Basale 1wk 4wk 8wk 12wk 24wk 
Triamcinolone  14.6 15.5 16.2 17.6 17.5 16.4 
Bevacizumab  14.8 15 14.7 15.1 14.3 14.2 
P  0.862 0.595 0.131 0.002 0.002 0.007 
 
Figure 1 Comparison of the clinical course of central macular
thickness between the triamcinolone acetonide injected eyes
(dark line) and the bevacizumab injected eyes (light line) in
patients with bilateral diffuse diabetic macular edema Each
square and vertical bar indicates mean central macular thickness 依
standard deviation (SD) of the mean.
Bevacizumab/triamcinolone for diabetic macular edema
552
陨灶贼 允 韵责澡贼澡葬造皂燥造熏 灾燥造援 8熏 晕燥援 3熏 Jun.18, 圆园15 www. IJO. cn
栽藻造押8629原愿圆圆源缘员苑圆 8629-82210956 耘皂葬蚤造押ijopress岳员远猿援糟燥皂
IVTA injections developed lens opacities. No cataract
surgery was performed during the follow-up period. Cataract
progression has not been observed in the IVB group.
DISCUSSION
Breakdown of inner blood-retinal barrier due to retinal
infiltration of inflammatory cells and biochemical alterations
arising from chronic hyperglycemia, plays an important part
in the pathogenesis of diabetic macular edema [11-13]. Focal
macular edema can be controlled by laser photocoagulation,
however, eyes with diffuse macular edema generally
demonstrate a resistance against therapy. Among treatment
strategies towards the pathogenesis of the disease, TA and
bevacizumab, alone or in combination with laser
photocoagulation, have produced successful results in the
treatment of DME [ 6 , 7 , 14 , 15] . In the studies by Chakrabarti
[16] and Marey and Ellakwa [17], the response to therapy
with bevacizumab showed superiority compared with
triamcinolone for DME. However, these studies differed
from that of Paccola [18], Isaac [19] and Lim [20],
Song [21] who demonstrated that intravitreal triamcinolone
was more efficient in reducing DME relative to bevacizumab.
And in the other study by Rensch [22], IVTA and IVB
did not differ markedly in term of their effects in improving
VA and reducing macular thickness. Which treatment is
more effective remains controversial. In these studies,
efficacy of IVTA and IVB therapies have been compared by
applying them on only one eye of different patients. Thus, in
our study, by considering that the influence of systemic risk
factors such as glycemic level, blood pressure, and
nephropathy may alter the efficacy of the drugs in every
individual, both eyes of the each patient received intravitreal
treatment of both drugs with equal volume were compared.
One of the potential limitation of this study is that, we used
only the macular scan pattern of the HD-OCT. As we used
just macular pattern of the HD-OCT instead of full field 3-D
SD-OCT, extrafoveal vitreous tractions including
vitreopapillary traction and extrafoveal traction membranes
which is a common fenomen in DDME, might not be
detected, as recently re-described by Ophir [23]. Thus, the
therapeutic effect of the two medications could be different if
all tractional components were excluded.
The most remarkable problem encountered in cases treated
with intravitreal injections is the transient nature of the
therapeutic effect and frequent recurrences. Pharmacokinetic
data suggest a single intravitreal injection of 1.25 mg
bevacizumab is effective for 6-7wk [24]. Kreutzer [25]
suggested that a single triamcinolone injection may be as
effective as a 3 injections of bevacizumab for the treatment
of DME. Less number of injections of triamcinolone reduces
injection-related complications and improve the patient
compliance. In a Meta-analysis including 6 study which
compare the efficacy of the IVTA versus IVB in the
treatment of DME shows IVTA is superior in improving VA
at earlier follow-up (1mo and 3mo) and in reducing CMT at
later follow -up (6mo) for DME [26]. In the current study,
visual acuity was observed to rise at 1 and 4wk and remain
stable at 8, 12, and 24wk in the IVTA group. Reduction
ratios for mean CMT values were 29% at 1wk, 38% at 4wk,
40% at 8wk, 38% at 12wk, and 38% at 24wk. Thus, CMT
demonstrated a tendency to increase starting from the 12wk
and therefore 6 (30%) eyes received a second IVTA injection
in the IVTA group.
In multicenter trial of Pan-American Collaborative Retina
Study Group (PACORES), 139 eyes of 115 DDME patients
received 1.25 mg and 2.5 mg IVB injection and the patients
were followed-up for a mean period of 24mo. No difference
was determined between the 1.25 and 2.5 mg doses with
regard to efficacy. While 95% of patients required a second
injection, 84% required a third injection, 36% required 6
injections, and 11% required 9 injections [6]. In the present
study, visual acuity in the IVB group increased at 1 and 4wk,
restarted to decrease at 8 and 12wk, and returned to the initial
levels at 24wk. The reduction ratios of mean CMT were
16.4% at 1wk, 16.8% at 4wk, 14% at 8wk, 7% at 12wk, and
16% at 24wk. Thus, CMT demonstrated a tendency to
increase starting from the 8th week and 15 (75%) eyes were
subjected to second bevacizumab injection at 12wk.
According to the literature and our results, the reduction in
CMT after intravitreal bevacizumab injection, can be
maintained only for about 1mo even with 2.5 mg injection,
macular thickness begins to reincrease and require a second
injection after 1mo.
A crossover effect of bevacizumab in the contralateral eye on
proliferative diabetic retinopathy has been reported [7].
However pharmacokinetic studies of intravitreal
bevacizumab injection revealed that only a very small
amounts of bevacizumab or no changes on VEGF levels were
detected in the contralateral eye [27,28]. And also in a PET/CT
study on small animals with I-124 radiolabeled bevacizumab
and ranibizumab showed that there were no significant
escape of bevacizumab and ranibizumab from the vitreous
cavity after intravitreal injection [29]. Although, it may be
concluded that bevacizumab may have some or little effect
on the contralateral eye, we did not establish a significant
effect primary eye. This study actually showed that IVB does
not have a beneficial effect in DDME and such edema may
be would naturally adversely affect the posterior macula over
time to irreversible changes.
The most common side effect observed after IVTA injection
is, raised IOP and its incidence ranges between 20%-80% in
various studies [30]. Considerable IOP increases are reported
even in small case series. On the other hand, clinical studies
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performed with bevacizumab have shown insignificant
alterations in IOP levels. In the present study, IOP levels at 4,
8, and 12wk exhibited a statistically significant elevation in
the IVTA group and remained stable at 24wk. However, IOP
levels in the IVB group demonstrated no significant change.
At routine doses of both drugs, bevacizumab may be more
advantageous than triamcinolone with regard to IOP stability.
There is only one study in the literature which compares
triamcinolone acetonide and bevacizumab therapies in the
same patients. In that study, Shimura [31] applied single
dose of bevacizumab 1.25 mg one eye of each of 14 patients
with bilateral persistant DME, while delivering single dose of
triamcinolone acetonide 4 mg on the contralateral eye, after
which the patients were followed-up for 24wk.
Triamcinolone acetonide was found to provide more efficient
and long-standing effect in terms of reducing CMT and
increasing visual acuity compared with the bevacizumab.
Bevacizumab the VEGF inhibitor which was used in our
study as well, provided a reduction in macular edema 4wk
after the injection, however, its effect was not as efficient as
triamcinolone acetonide and macular edema relapsed at
12wk. While the reduction in CMT one week after the
injection was 16% for the IVB group, it was 29% for the
IVTA group. CMT reduction rate was 7% in the IVB group
12wk after the injection which is an evidence indicating a
decrease in the effect of bevacizumab. On the other hand,
CMT reduction rate among triamcinolone acetonide group
was still 38% which shows the continuation of the influence
of triamcinolone injection even after 12wk. At 12wk, 75% of
IVB group and 30% of IVTA group received a second
injection due to recurrence of macular edema.
Our results showed earlier and more frequent recurrences in
the eyes treated with bevacizumab compared with the ones
treated with triamcinolone. Therefore, in order to prolong the
reductive effect, multiple injections of bevacizumab required.
DME is not only associated with VEGF, but also with many
growth factors and inflammatory cytokines. Bevacizumab
reduces vascular permeability by blocking the influence of
VEGF. Triamcinolone acetonide decreases VEGF
expression, prevents fluid accumulation in the extracellular
area, and inhibits release of edema-inducing inflammatory
mediators. In this regard, triamcinolone is a multipotent drug
and has more advantages when compared with bevacizumab
which only reduces intraocular VEGF levels. In the current
study, 6mo follow-up results of each drug regimen with the
same volume and same patient were presented, however,
studies with longer duration and larger sample size are
required in order to further evaluate multiple dose-response
relationship and safety of the drugs.
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